HUTCHMED (China) (HCM) Shares Outstanding (2014 - 2026)
HUTCHMED (China) (HCM) posted quarterly Shares Outstanding (Entity) of $173.2 million for Q2 2026, up 1.02% year-over-year from $171.4 million in Q2 2025, and up 0.87% quarter-over-quarter from $171.7 million in Q4 2025.
HUTCHMED (China) (HCM) Shares Outstanding (2014 - 2026) Analysis & Trends
HUTCHMED (China) (HCM) has reported Shares Outstanding (Entity) for 13 consecutive years, with $173.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 1.02% year-over-year to $173.2 million; the TTM figure through Jun 2026 stood at $173.2 million (up 1.02% YoY), while the FY2025 annual figure was $171.7 million, changed 0.34% from the prior year.
- Shares Outstanding (Entity) improved to $173.2 million in Q2 2026 per HCM's latest filing, from $171.7 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $173.2 million in Q2 2026 and bottomed at $169.4 million in Q2 2023.
- Historically, Shares Outstanding (Entity) has averaged $170.8 million across 5 years, with a median of $171.1 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) increased 16.46% — and 2023, when it retreated 0.28%.
- HUTCHMED (China)'s Shares Outstanding (Entity) stood at $169.4 million in 2022, then gained by 0.3% to $169.9 million in 2023, then gained by 0.67% to $171.1 million in 2024, then gained by 0.34% to $171.7 million in 2025, then increased by 0.87% to $173.2 million in 2026.
- Business Quant data shows HCM's Shares Outstanding (Entity) at $173.2 million in Q2 2026, $171.7 million in Q4 2025, and $171.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 832.44 Mn |
| 10 | HUTCHMED (China) | 2.16 Bn | 2.16 Bn | - | 173.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 865.77 Mn |
| Dec 31, 2025 | 858.28 Mn |
| Jun 30, 2025 | 857.04 Mn |
| Dec 31, 2024 | 855.35 Mn |
| Jun 30, 2024 | 856.03 Mn |
| Dec 31, 2023 | 849.65 Mn |
| Jun 30, 2023 | 846.93 Mn |
| Dec 31, 2022 | 847.14 Mn |
| Jun 30, 2022 | 849.28 Mn |
| Dec 31, 2021 | 792.68 Mn |
| Jun 30, 2021 | 729.24 Mn |
| Mar 31, 2021 | 723.18 Mn |
| Dec 31, 2020 | 697.93 Mn |
| Jun 30, 2020 | 685.29 Mn |
| Mar 31, 2020 | 683.86 Mn |
| Dec 31, 2019 | 665.68 Mn |
| Sep 30, 2019 | 665.61 Mn |
| Jun 30, 2019 | 665.55 Mn |
| Mar 31, 2019 | 665.47 Mn |
| Dec 31, 2018 | 664.26 Mn |